Oncotarget
Oncotarget Podcast
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Episodes
Mentioned books
Mar 19, 2024 • 2min
“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny
Dr. Blagosklonny discusses the drawbacks of osimertinib in lung cancer treatment and proposes preemptive combinations to increase PFS without harm. The podcast delves into the effectiveness of different combinations for EGFR mutant lung cancer and MET-driven lung cancer.
Mar 18, 2024 • 4min
A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation
Researchers from various institutions discuss the G-quadruplex landscape and its regulation in DNA, challenging conventional beliefs. They explore a new antibody capture method to study G4s without bias, shedding light on their distribution and regulation in the genome.
Mar 14, 2024 • 5min
Antitumor Effects of Sacituzumab Govitecan Plus Platinum-Based Chemotherapy
Researcher Thomas M. Cardillo discusses the synergistic anti-tumor effects of Sacituzumab Govitecan with platinum-based chemotherapy in inhibiting cancer cell growth. They explore significant tumor regressions in mice tumor models, showing promise for clinical investigation in solid tumor treatment revolution.
Mar 11, 2024 • 2min
Oncotarget at AACR Annual Meeting 2024
Exploring Impact Journals and Onco Target at AACR Annual Meeting 2024: Discussion on the dedication of Impact Journals to publishing scholarly works in biomedical sciences, focusing on cancer and aging research. Highlighting their participation at AACR, emphasizing insightful peer review and interdisciplinary collaboration in oncology and biomedical fields.
Mar 6, 2024 • 4min
GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells
Researchers investigate GZ17-6.02 compound in killing multiple myeloma cells. Study shows efficacy against inhibitor-resistant cells. Synergistic effects with proteasome inhibitors on key cell death pathways. Podcast explores potential of GZ17-6.02 in cancer treatment.
Mar 4, 2024 • 3min
Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas
Researchers discuss the significant antitumor effects of combining Sacituzumab govitecan with platinum-based chemotherapy in triple-negative breast, urinary bladder, and small-cell lung carcinomas. Promising results are seen in mouse models with this combination treatment.
Feb 28, 2024 • 4min
BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula
Exploring the prevalence of BRCA1 and BRCA2 mutations in ovarian cancer patients from Southern Italy, shedding light on the importance of genetic testing and its implications for treatment and prevention strategies.
Feb 26, 2024 • 4min
GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells
Researchers discuss the effectiveness of GZ17-6.02 in killing Mycosis Fungoides cells by activating various signaling pathways and inducing mitochondrial dysfunction
Feb 22, 2024 • 7min
Raw Areca Nut Betel Quid Consumption and Esophageal Cancer
Exploring the traditional practice of beetlequid chewing in regions like India and its link to oral, esophageal, and gastric cancers. Researchers delve into the role of the Mad2 gene in the development of esophageal cancer, shedding light on the mechanisms of gene deregulation and its implications for diagnosis and treatment.
Feb 21, 2024 • 2min
Combining Causal and Correlative Approaches to Discover Response Biomarkers to Paclitaxel
Researchers discuss the discovery of a potential predictive biomarker for paclitaxel response in glioblastoma and breast cancer. Validation in patient cohorts and ongoing clinical trials are crucial for personalized medicine. Exploring new biomarkers is essential for improving therapeutic efficacy in conditions with variable treatment responses such as glioblastoma.
